Drug Discovery World

FEBRUARY 5, 2024

Product launches More than 400 exhibitors are at the event this year, many of whom are launching new products. Yokogawa are taking advantage of the occasion to announce an expansion to its CellVoyager family of products: CQ3000, a high-content analysis system for capturing high-definition 3D microscopic images of live cell cultures.

Gene Therapy 64

Gene Therapy Life Science Production Dermatology 64

Drug Discovery World

AUGUST 9, 2023

The life sciences sector has seen significant M&A activity over the last few weeks. The news followed an announcement that Biogen would be cutting around 1,000 jobs, or 11% of its workforce, to allow investment into its product pipeline. DDW’s Diana Spencer provides an overview.

Drugs 52

Drugs Drug Delivery Systems Drug Delivery Life Science 52

Pharmaceutical Technology

NOVEMBER 21, 2022

RVAC Medicines has signed a master research partnership agreement with the Agency for Science, Technology and Research (A*STAR) for analysing and developing solutions to build messenger ribonucleic acid (mRNA) manufacturing and analytics expertise in Singapore.

Manufacturing 130

Manufacturing Medicine Vaccination Vaccine 130

Roots Analysis

FEBRUARY 29, 2024

The drug is a folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC) and potent anti-tumor activity in preclinical endometrial cancer patient-derived xenograft (PDX) models. Sutro Biopharma, Inc., Sutro Biopharma, Inc., CD22 is another notable target antigen, which is being targeted by 7% of the candidates.

Antibody 40

Antibody Licensing Licensing Development 40

Pharmaceutical Technology

SEPTEMBER 5, 2022

Until 2025, we have strong growth ahead of us, but we also believe we can continue to grow very strongly post-2025 and it’s all about innovation in the pipeline.”. The world of science is a big ocean, and we have to look for ideas and projects where they are.”. “We want to be a sustainably growing company. billion in development.

FDA Approval 287

FDA Approval Clinical Trials Clinical Trials Development 287

Drug Discovery World

APRIL 17, 2024

DDW’s Diana Spencer speaks to Josh Mandel-Brehm , CEO of Massachusetts-based biotech CAMP4, to understand the role regulatory RNAs play in gene expression and how the founders overcame the challenge of launching a business based on brand new science. What are the challenges of drug discovery in this area? Can you give some examples?

Gene Expression 59

Gene Expression Gene Genetic Disease RNA 59

Drug Discovery World

FEBRUARY 19, 2024

Dr Julie Warner is Vice President of Regulatory Affairs at drug development consultancy, Boyds. In this article, she provides her expert insights into the key trends and developments expected to shape the global drug development industry this year. antibody-drug conjugate [ADC] pipelines in some oncology settings).

Development 59

Development Gene Therapy Drugs Antibody 59

Pharma Marketing Network

MARCH 2, 2022

New findings from an IQVIA report show the biopharmaceutical industry is sparking with activity with an astounding 6,000 products in development and new geographical locations seeing the boom. IQVIA’s lower success rate can be attributed to “tougher clinical challenges taken on by drug companies.”

Drugs 52

Drugs Life Science Production Gene Therapy 52

Roots Analysis

FEBRUARY 28, 2024

What is RMAT designation : Established under the 21st Century Cures Act, RMAT designation is a dedicated program designed to expedite the drug development and review processes for promising regenerative medicines and advanced therapies, including CAR T cell therapies.

Immune Response 52

Immune Response Development Medicine Drugs 52

Pharma Marketing Network

MARCH 2, 2022

New findings from an IQVIA report show the biopharmaceutical industry is sparking with activity with an astounding 6,000 products in development and new geographical locations seeing the boom. IQVIA’s lower success rate can be attributed to “tougher clinical challenges taken on by drug companies.”

Drugs 52

Drugs Life Science Production Gene Therapy 52

Drug Discovery World

FEBRUARY 16, 2024

million in grant funding to develop new drugs using its AI-driven drug discovery platform. The company, which is a spin-out from the Queen’s University Belfast, was established in 2021 to commercialise a drug discovery platform developed by researchers in the School of Biological Science at Queen’s.

Licensing 59

Licensing Licensing Drugs Development 59

Pharmaceutical Technology

SEPTEMBER 7, 2022

This follows the US Food and Drug Administration's (FDA) recent approval, in January this year, of Roche’s Vabysmo (faricimab) for DME, coupled with the anticipated approval of pipeline therapies in the forecast period from 2021 to 2031, which are expected to drive the growth of the DME market in the 7MM.

Marketing 130

Marketing Branding Protein Drugs 130

Pharmaceutical Technology

JULY 28, 2022

Looking ahead, the bulk of the current late-stage pipeline for wAMD mirrors what is commercially available, such as anti-vascular endothelial growth factor (VEGF) therapies, although different members of the VEGF family may be targeted depending on the therapy that is being developed.

Marketing 130

Marketing Gene Therapy FDA Approval Doctors 130

Drug Discovery World

JULY 31, 2023

The news follows an announcement by the company last week that it would cut around 1,000 jobs, or 11% of its workforce, to allow investment into its product pipeline. The post Biogen acquires Reata and cuts 1,000 jobs appeared first on Drug Discovery World (DDW).

FDA Approval 52

FDA Approval Production Clinical Trials Clinical Trials 52

Drug Discovery World

MARCH 23, 2023

Aldena Therapeutics, a biotech company that is pioneering siRNA-based therapies for dermatological indications, has updated its immuno-dermatology pipeline, appointed a Scientific Advisory Board (SAB), and announced $30 million financing by Medicxi. appeared first on Drug Discovery World (DDW).

Dermatology 52

Dermatology Life Science Production Scientist 52

pharmaphorum

APRIL 13, 2022

GlaxoSmithKline has agreed a deal to buy Sierra Oncology and its lead drug momelotinib for anaemia associated with the blood cancer myelofibrosis, sending the US biotech’s shares skywards. Sierra acquired momelotinib from Gilead Sciences in 2018 after equivocal results in earlier phase 3 myelofibrosis studies.

Sales 104

Sales Production Antibody Trials 104

Drug Discovery World

AUGUST 9, 2022

Provider to the life sciences industry BioIVT has acquired enzymes manufacturer Cypex in a bid to enhance its product portfolio. . Based in Dundee, Cypex manufactures recombinant xenobiotic metabolizing enzymes with its product portfolio covering a wide range of proteins involved in drug metabolism. .

In-Vitro 52

In-Vitro Protein Production Bacteria 52

Pharmaceutical Technology

SEPTEMBER 29, 2022

Sanofi will also make tiered royalty payments on net sales of products resulting from the collaboration in the future. Scribe’s CasX-Editors (XE), a suite of custom engineering genome editing and delivery tools based on new foundations such as the CasX enzyme, will back Sanofi’s developing NK cell therapies pipeline for cancer.

Development 130

Development In-Vivo Genome Genomics 130

Drug Discovery World

FEBRUARY 12, 2024

DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. Cameron Ross, SVP, Generative AI, Elsevier “AI has the potential to dramatically shorten one of the most costly areas of early drug development – small molecule discovery.

Genome 139

Genome Genomics Life Science Gene Therapy 139

pharmaphorum

JANUARY 11, 2023

A slow journey to drug discovery. Asked about the impetus behind Verseon’s work in the sector, Prakash explained that he began the company “to change the way the world finds new drugs”. Today’s pharmaceutical drug discovery process essentially relies on trial and error,” he expanded. “To Not an unambitious goal.

Big Data 120

Big Data Drugs Clinical Trials Clinical Trials 120

Drug Discovery World

MAY 5, 2023

Eterna Therapeutics, a life science company focused on mRNA cell engineering, has acquired Exacis Biotherapeutics’ immuno-oncology platform. The acquisition will provide Eterna with a pipeline of allogeneic immuno-oncology products under development for the treatment of haematologic and solid tumours.

Gene Editing 52

Gene Editing Engineer DNA Life Science 52

Pfizer

JANUARY 17, 2023

Share. • State-of-the-art biologics drug substance facility will produce Pfizer’s innovative pipeline products and provide additional capacity for in-line medicines. • Expected to more than double the current workforce of new facility by 2025. Pfizer to Acquire Sanford, North Carolina Manufacturing Site from Abzena.

Manufacturing 85

Manufacturing Containment Development Medicine 85

The Pharma Data

MAY 26, 2023

Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting will present data across its Oncology portfolio and growing pipeline, covering multiple tumor types and novel mechanisms of action at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2 through June 6.

Medicine 52

Medicine Clinical Development Antibody Development 52

Drug Discovery World

OCTOBER 16, 2023

The United Kingdom has established itself as a hub for drug discovery expertise worldwide. There is a range of reasons why this area has become focal point for drug discovery, one of which is the fact that it encompasses the University of Oxford and the University of Cambridge, two of the oldest and most prestigious universities in the world.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Pharmaceutical Technology

DECEMBER 14, 2022

GSK has entered a strategic partnership with Wave Life Sciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. Wave will conduct all preclinical research for the programmes of both companies until investigational new drug (IND)-facilitating studies. .

Life Science 162

Life Science Development Gene Therapy Genetics 162

Pharmaceutical Technology

DECEMBER 22, 2022

This consists of any projects that have expanded the company’s footprint in the sector, including: contract wins; launching in new territories; launching new product lines; the acquisition and expansion of facilities and real estate; acquisition of new machinery or other assets; improved logistics; partnerships; and significant staff increases.

Insulin 130

Insulin Production Development Genetics 130

Drug Discovery World

MARCH 13, 2024

With government support and strong academic institutions, does Singapore have what it takes to become a global centre for life sciences? DDW’s Diana Spencer explores how the country is turning pioneering science into a successful biotech industry. UK-based molecular diagnostics group Yourgene operates in Singapore.

Life Science 69

Life Science Genome Genomics Research 69

pharmaphorum

SEPTEMBER 30, 2022

Novel oncologic drugs continue to command premium pricing, driven by a combination of unmet needs, and delivering often-iterative, sometimes-significant improvements in survival or maintenance of a progression-free state. The former of these drugs, BeiGene’s tislelizumab, launched in its native China at prices over 60% lower than Keytruda.

Life Science 95

Life Science Marketing Drugs Production 95

pharmaphorum

FEBRUARY 9, 2022

GlaxoSmithKline’s COVID-19 products – antibody drug Xevudy and a vaccine adjuvant – helped drive a 5% increase in 2021 revenues to £34 billion ($46 billion), ahead of what chief executive Emma Walmsley says will be a “landmark year” for the company. billion, but still came in ahead of analyst expectations.

Sales 101

Sales Production Vaccination Vaccine 101

Pharmaceutical Technology

OCTOBER 6, 2022

According to Adam Bradbury, GlobalData PharmSource analyst “[…] evidence indicates that containment facilities are in high demand and will be increasingly so in future as the oncology pipeline and the use of cytotoxic drugs continues to grow.” These turnkey solutions cover every process through the drug manufacturing life cycle.

Engineer 130

Engineer Containment Production Manufacturing 130

Pharmaceutical Technology

JUNE 27, 2022

The focus of this strategic alliance will be on drug candidates, repotrectinib and elzovantinib (TPX-0022). This alliance will see clinical trial infrastructure and expertise of MD Anderson being brought together with differentiated targeted oncology pipeline of Turning Point.

Clinical Trials 147

Clinical Trials Clinical Trials Genetics Development 147

pharmaphorum

FEBRUARY 14, 2022

A recent report has found that R&D productivity rose vertiginously during 2021, but how much of this was organic and how much can be attributed to the pandemic? Where COVID-19’s impact can be seen is the estimated return expected to be garnered from the pipeline. In 2020, the development cycle averaged 7.14 More than meets the eye.

Production 98

Production Clinical Trials Clinical Trials Sales 98

pharmaphorum

MARCH 10, 2022

In little over three decades, advances in biotechnology have noticeably disrupted the development landscape of small molecule drugs. Now, amid a wave of innovation, investors and drugmakers are putting their weight behind the drug class. Investing in biological production facilities. The rise of biologics.

Production 98

Production Life Science Development Gene Therapy 98

XTalks

APRIL 5, 2024

Amylyx Pharmaceuticals announced yesterday that it will be pulling its ALS (amyotrophic lateral sclerosis) drug Relyvrio from the market after failing in a confirmatory trial. As its first and only commercial product, Relyvrio was the only source of revenue for the Massachusetts-based biotech, which was founded 11 years ago.

Trials 98

Trials Drugs Marketing FDA Approval 98

Pharmaceutical Technology

JANUARY 12, 2023

The collaboration will use the vector biology, manufacturing capabilities and the drug development experience of Solid Biosciences and Phlox Therapeutics’ knowledge in genetic cardiomyopathies and RNA therapies. Solid Biosciences stated that the partnership boosts its scientific capabilities along with commercial potential in cardiac therapy.

RNA 130

RNA Gene Therapy Genetics Genetic Disease 130

Drug Discovery World

JULY 22, 2022

Synthetic biology is an emerging field of science that combines methodologies from engineering and biology to design or re-design biological systems to produce useful and sustainable new products. The UK has a leading position in the fundamental science, and the sector is growing thanks to support from initiatives like SynbiCITE.

DNA 52

DNA Life Science Engineer Development 52

pharmaphorum

DECEMBER 2, 2020

Swiss biotech Noema has raised 54 million Swiss francs ($59m) to develop four neurological disorder drugs licensed in from Roche. The company is developing four phase 2 drugs brought in from Roche after the big Swiss pharma decided somebody else should take the risk of developing them.

Development 62

Development Drugs Licensing Licensing 62